Teleflex Q2 adj. EPS $3.73 beats $3.42 YoY; raises FY outlook on BIOTRONIK deal

TELEFLEX INC

2025-Q2 EPS reported $4.82 revenue$1,481,558,000

GAAP revenue $780.9M (+4.2% YoY); adjusted constant currency revenue growth +1.0%.
GAAP diluted EPS $2.77 vs $1.69; adjusted diluted EPS $3.73 vs $3.42.
Full-year GAAP revenue growth guidance raised to 9.0%-10.0% (from 1.3%-2.3%) due to BIOTRONIK acquisition.
FY adjusted diluted EPS guidance raised to $13.90-$14.30 from $13.20-$13.60.
Interventional segment revenue surged 20.4% as reported; OEM and Interventional Urology each declined over 8%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.